AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23519724 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2.5
Number of subjects: 110
Study 23520042 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated method for segmentation of renal cysts using morphologic watershed technique with shape-detection level set.
Number of subjects: 20
Study 23520311 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg clarithromycin once daily
Number of subjects: 5
Study 23520311 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg clarithromycin once daily
Number of subjects: 5
Study 23520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Number of subjects: 409
Study 23520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength test
Number of subjects: 409
Study 23520321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test and handgrip strength test
Number of subjects: 409
Study 23522299 — intervention group
Group type: EXPERIMENTAL
Intervention: Template-assisted transperineal prostate biopsy (TTPB)
Number of subjects: 87
Study 23522337 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention through a 16-week supervised diet program including formula products and dietetic counselling.
Number of subjects: 169
Study 23522439 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (CM)
Number of subjects: 166
Study 23522439 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (SM)
Number of subjects: 166
Study 23522439 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management with ischemia
Number of subjects: 166
Study 23522439 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin as a risk factor
Number of subjects: 166
Study 23523454 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 5130
Study 23523460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical recanalization using a Solitaire FR revascularization device
Number of subjects: 40
Study 23523668 — intervention group
Group type: EXPERIMENTAL
Intervention: High AREE tertile (activity related energy expenditure)
Number of subjects: 82
Study 23523668 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle AREE tertile
Number of subjects: 82
Study 23523668 — intervention group
Group type: COMPARATOR
Intervention: Low AREE tertile
Number of subjects: 82
Study 23523668 — intervention group
Group type: COMPARATOR
Intervention: Female participants
Number of subjects: 82
Study 23524045 — intervention group
Group type: EXPERIMENTAL
Intervention: Disconnect-reconnect technique
Number of subjects: 0
Study 23524045 — intervention group
Group type: COMPARATOR
Intervention: Push-pull technique
Number of subjects: 0
Study 23524640 — intervention group
Group type: EXPERIMENTAL
Intervention: T-replete second SCT
Number of subjects: 59
Study 23524640 — intervention group
Group type: COMPARATOR
Intervention: Non-SCT treatments
Number of subjects: 59
Study 23524640 — intervention group
Group type: COMPARATOR
Intervention: Non retransplanted patients
Number of subjects: 59
Study 23524863 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 0
Study 23525305 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009 (H1N1) virus-like strain vaccination
Number of subjects: 138
Study 23525420 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shocks for adjudicated ventricular tachyarrhythmias
Number of subjects: 1177
Study 23525420 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mortality
Number of subjects: 1177
Study 23525441 — intervention group
Group type: EXPERIMENTAL
Intervention: Squalene concentrations in women
Number of subjects: 2616
Study 23525441 — intervention group
Group type: EXPERIMENTAL
Intervention: Squalene concentrations in men
Number of subjects: 2616
Study 23525441 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol absorption markers
Number of subjects: 2616
Study 23525751 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for acute ACL tear, specific intervention details not available.
Number of subjects: 0
Study 23525751 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available.
Number of subjects: 0
Study 23526734 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT guided LM/SL
Number of subjects: 14
Study 23526734 — intervention group
Group type: COMPARATOR
Intervention: LM/SL plus SPECT/CT
Number of subjects: 14
Study 23527091 — intervention group
Group type: EXPERIMENTAL
Intervention: M2e-VLPs containing nucleic acids
Number of subjects: 0
Study 23527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted M2e-VLPs containing nucleic acid-binding domain
Number of subjects: 0
Study 23527091 — intervention group
Group type: COMPARATOR
Intervention: M2e-VLPs with or without nucleic acids
Number of subjects: 0
Study 23529375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with radiotherapy and temozolomide
Number of subjects: 0
Study 23529375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23530004 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients
Number of subjects: 30
Study 23530004 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 23530011 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cannabis smoking
Number of subjects: 30
Study 23530011 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 23530013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (presurgery period)
Number of subjects: 10
Study 23530013 — intervention group
Group type: COMPARATOR
Intervention: RYGB surgery with daily matched diet (postsurgery period)
Number of subjects: 10
Study 23530013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both periods (primary outcome)
Number of subjects: 10
Study 23530485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) on admission ECG
Number of subjects: 30
Study 23530485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) post intervention ECG
Number of subjects: 30
Study 23530485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency morphology index (HFMI) at 24h ECG
Number of subjects: 30
Study 23530485 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HFMI from admission ECG to 24h ECG
Number of subjects: 30
Study 23530572 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-FU derivatives (specific regimens not detailed)
Number of subjects: 2128
Study 23530577 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 0
Study 23530663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) administered as a 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity.
Number of subjects: 53
Study 23530663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) at doses escalating from 7 to 259 mg/m(2).
Number of subjects: 53
Study 23530663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) at 200 mg/m(2) given IV at Days 1, 8, and 15 every 4 weeks.
Number of subjects: 53
Study 23530709 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 130
Study 23530817 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Questionnaire (ACQ)
Number of subjects: 8000
Study 23530817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Asthma Quality of Life Questionnaire (Mini-AQLQ)
Number of subjects: 8000
Study 23530817 — intervention group
Group type: EXPERIMENTAL
Intervention: Morisky Medication Adherence Scale (MMAS-4)
Number of subjects: 8000
Study 23530817 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment strategies and associated healthcare costs
Number of subjects: 8000
Study 23530817 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled/poorly controlled asthma patients
Number of subjects: 8000
Study 23531228 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 75
Study 23531361 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.3 g·kg-1 body mass)
Number of subjects: 8
Study 23531361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.045 g·kg-1 body mass NaCl)
Number of subjects: 8
Study 23531361 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 8
Study 23531361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Average RNFL thickness
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior hemisphere average thickness
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior quadrant average thickness
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical cup-to-disc ratio
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rim area
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rim volume
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: GCC average thickness
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: GCC inferior thickness
Number of subjects: 142
Study 23532529 — intervention group
Group type: EXPERIMENTAL
Intervention: GCC superior thickness
Number of subjects: 142
Study 23533013 — intervention group
Group type: EXPERIMENTAL
Intervention: AMB-Home (nurse-led in-home cognitive behavioral program)
Number of subjects: 194
Study 23533230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab plus androgen deprivation therapy (ADT) consisting of bicalutamide and goserelin for 13 weeks before prostatectomy
Number of subjects: 29
Study 23533230 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 29
Study 23533264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 3
Study 23535095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization protocol (200 mL)
Number of subjects: 36
Study 23535095 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 children)
Number of subjects: 36
Study 23535095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization protocol
Number of subjects: 36
Study 23535105 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 8 weeks followed by 44 weeks of weight maintenance
Number of subjects: 91
Study 23535761 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 0.03 mg/kg single dose
Number of subjects: 38
Study 23535761 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 0.01 to 0.03 mg/kg once daily for 8 weeks
Number of subjects: 38
Study 23535954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg + radiotherapy (8 Gy/lesion)
Number of subjects: 50
Study 23535954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 50
Study 23535954 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg - Monotherapy
Number of subjects: 50
Study 23536265 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD group
Number of subjects: 287
Study 23536265 — intervention group
Group type: COMPARATOR
Intervention: Non-CKD group
Number of subjects: 287
Study 23536386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodialysis (CVVHD)
Number of subjects: 20
Study 23536883 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet counseling provision
Number of subjects: 282
Study 23536883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist characteristics associated with diet counseling
Number of subjects: 282
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal Abdominal Diameter (SAD)
Number of subjects: 255
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 255
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (apoB)
Number of subjects: 255
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 255
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 255
Study 23536999 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol or LDL-cholesterol
Number of subjects: 255
Study 23537041 — intervention group
Group type: COMPARATOR
Intervention: Lixisenatide (10 weeks treatment after ischemia-reperfusion)
Number of subjects: 0
Study 23537041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (acute treatment during ischemia-reperfusion)
Number of subjects: 0
Study 23537041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (in isolated cardiomyocytes)
Number of subjects: 0
Study 23537041 — intervention group
Group type: COMPARATOR
Intervention: Lixisenatide (chronic treatment)
Number of subjects: 0
Study 23537121 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) and systemic antibiotics
Number of subjects: 29
Study 23537365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LPS inhalation (2 μg)
Number of subjects: 12
Study 23537365 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast treatment (5 days) before last LPS challenge
Number of subjects: 12
Study 23537458 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg
Number of subjects: 0
Study 23537458 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg
Number of subjects: 0
Study 23537458 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin 100 mg
Number of subjects: 0
Study 23537966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendavia at 0.05 mg/kg per hour
Number of subjects: 300
Study 23537966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically appearing) administered as an intravenous infusion at 60 mL/h
Number of subjects: 300
Study 23537966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendavia
Number of subjects: 300
Study 23537966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 23537969 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute device implantation
Number of subjects: 478
Study 23537969 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 478
Study 23537971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal middle cerebral artery pulsatility index (MCA-PI) z-scores
Number of subjects: 230
Study 23537971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal cerebrovascular resistance (lower MCA-PI z-scores)
Number of subjects: 230
Study 23537968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) + standard therapy
Number of subjects: 692
Study 23537968 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 692
Study 23537968 — intervention group
Group type: EXPERIMENTAL
Intervention: PCDT + standard therapy
Number of subjects: 692
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) increase
Number of subjects: 61
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: New embolic events in DW-MRI
Number of subjects: 61
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological deficit assessed by NIHSS
Number of subjects: 61
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of NSE and new emboli in DW-MRI
Number of subjects: 61
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of concomitant comorbidities
Number of subjects: 61
Study 23538093 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sufficiency and all-cause mortality after 30 days and one year
Number of subjects: 61
Study 23538524 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (13-valent pneumococcal conjugate vaccine)
Number of subjects: 193
Study 23538866 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (CT)
Number of subjects: 353
Study 23538866 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs
Number of subjects: 353
Study 23539736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour OGTT glucose of >155 mg/dL
Number of subjects: 474
Study 23541126 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5-225 mg/d)
Number of subjects: 865
Study 23541126 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotype
Number of subjects: 865
Study 23541189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg/d)
Number of subjects: 254
Study 23541189 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (15 mg)
Number of subjects: 254
Study 23541189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 23541299 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office screening tool for assessing fitness to drive
Number of subjects: 1230
Study 23541331 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical, unilateral carotid body resection
Number of subjects: 1
Study 23542776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trunk and gluteal NMES
Number of subjects: 7
Study 23542776 — intervention group
Group type: COMPARATOR
Intervention: Control (no NMES)
Number of subjects: 7
Study 23542823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation (FMT) - freshly prepared fecal enemas daily for 5 days
Number of subjects: 10
Study 23543609 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazoles (62.7%) and echinocandins (34.2%) were the most commonly used antifungal agents; first-line therapy was typically fluconazole (37.7%).
Number of subjects: 306
Study 23543609 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antifungal susceptibility.
Number of subjects: 306
Study 23543609 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiated after diagnostic confirmation in 166/268 (61.9%) patients.
Number of subjects: 306
Study 23543660 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily for 18 to 24 months)
Number of subjects: 21
Study 23544203 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system (with the system on and a 1-to-1 mapping of spatial information)
Number of subjects: 28
Study 23544203 — intervention group
Group type: COMPARATOR
Intervention: Residual vision
Number of subjects: 28
Study 23544203 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system (with the system on but with randomly scrambled spatial information)
Number of subjects: 28
Study 23544203 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal spatial information (follow-up testing)
Number of subjects: 28
Study 23544203 — intervention group
Group type: COMPARATOR
Intervention: Scrambled spatial information (follow-up testing)
Number of subjects: 28
Study 23545055 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 23545708 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9,39) at 30 pmol/kg/min
Number of subjects: 4
Study 23545708 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9,39) at 300 pmol/kg/min
Number of subjects: 4
Study 23545708 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4
Study 23545708 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1-(9,36)amide
Number of subjects: 4
Study 23547075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose range of 24 to 54 Gy in six fractions
Number of subjects: 102
Study 23547075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 102
Study 23547218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2 × 500 mg added to current biologic and nonbiologic DMARD treatment
Number of subjects: 176
Study 23547558 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-174 (600, 800, or 1000 μg/m²) administered as intravenous infusion, twice weekly for a total of 5, 10, or 15 injections.
Number of subjects: 17
Study 23547655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (average daily dose of at least 720 mg)
Number of subjects: 123
Study 23547655 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic response to nilotinib
Number of subjects: 123
Study 23547655 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow monophasic response to nilotinib
Number of subjects: 123
Study 23547655 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR-ABL1 (IS) ≤ 10% at 6 months
Number of subjects: 123
Study 23547778 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic infections (OIs) in the prior three months
Number of subjects: 1094
Study 23547778 — intervention group
Group type: COMPARATOR
Intervention: No opportunistic infections (OIs) in the prior three months
Number of subjects: 1094
Study 23547778 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CD4+ T cell count changes
Number of subjects: 1094
Study 23547837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation after fludarabine-based induction
Number of subjects: 0
Study 23548165 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of [(14)C]pazopanib in suspension (400 mg, 70 µCi)
Number of subjects: 10
Study 23548165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 5 mg pazopanib followed by oral administration of 800 mg pazopanib tablet once daily for 26 days
Number of subjects: 10
Study 23548728 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid therapy (ATT) for 4 months
Number of subjects: 10
Study 23548879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous synthetic human secretin (sHS) 0.05-0.8 µg/kg for 3 days
Number of subjects: 12
Study 23549489 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital management of patients on warfarin undergoing PCI-S
Number of subjects: 411
Study 23549489 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (warfarin, aspirin, and clopidogrel) prescription at discharge
Number of subjects: 411
Study 23549489 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-low thromboembolic risk
Number of subjects: 411